IP Library › Granted Patent US 7,119,118
Granted Patent B2
US 7,119,118 · App. 10/191,430 · Granted Oct 10, 2006

Highly purified ethyl EPA and other EPA derivatives for treatment of huntington's disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,119,118
App. No.
10/191,430
Granted
Oct 10, 2006
Kind
B2
Abstract

A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.

Claims (26)

1. A method of treating Huntington's disease

comprising administering to a subject a pharmaceutical preparation consisting essentially of EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% by weight is in the form of EPA, and wherein less than 5% by weight is in the form of docosahexaenoic acid (DHA).

2. The method of claim 1 , wherein of all the fatty acids present in the preparation at least 95%, is in the form of EPA.

3. The method of claim 1 , wherein of all the fatty acids present in the preparation less than 3% is in the form of docosahexaenoic acid (DHA).

4. The method of claim 1 , wherein among the fatty acids present, other than docosahexaenoic acid (DHA) and EPA, there are less than 3% of each of AA or DPA-n-3, individually.

5. The method of claim 1 , wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 5% of the total fatty acids present.

6. The method of claim 1 , wherein the EPA is selected from group consisting of:

a) ethyl-EPA;

b) lithium EPA;

c) mono-, di- and triglyceride EPA;

d) an ester or salt of EPA; and

e) a free acid form of EPA.

7. The method of claim 1 , further comprising administering to the subject a pharmaceutical composition which is a psychiatric or neurological drug that acts on neurotransmitter metabolism or receptors.

8. The method of claim 7 , wherein the pharmaceutical composition is formulated together with the pharmaceutical preparation.

9. The method of claim 7 , wherein the pharmaceutical composition is present in a therapeutically effective amount.

10. The method of claim 1 , wherein the EPA is ethyl-EPA.

11. The method of claim 1 , wherein the EPA is lithium-EPA.

12. The method of claim 1 , wherein the EPA is present as a monoglyceride, a diglyceride, a triglyceride, or a combination thereof.

13. The method of claim 1 , wherein the EPA is an ester or a salt of EPA.

14. The method of claim 1 , wherein the EPA is a free acid form of EPA.

15. The method of claim 1 , wherein the pharmaceutical preparation comprising EPA is in capsule form.

16. The method of claim 15 , wherein the capsule form is a gelatin capsule.

17. The method of claim 1 , wherein the EPA is administered in a daily dose in the range of 0.05 to 50 g/day.

18. The method of claim 1 , wherein the EPA is administered in a daily dose in the range of 0.1 to 10 g/day.

19. The method of claim 1 , wherein the EPA is administered in a daily dose in the range of 0.5 to 5 g/day.

20. The method of claim 1 , wherein the EPA is administered in a daily dose in the range of about 1 to about 2 g/day.